Skip to main content

Outlook for Ophthalmologists Cloudy After Medicare Changes


uly 27, 2012 — When the Centers for Medicare and Medicaid Services (CMS) announced on July 6 that it intended to substantially slash reimbursements for a broad range of specialists to underwrite the expense of raising payments for primary care physicians by up to 7%, ophthalmologists were among the specialists who emerged largely unscathed.
Ophthalmologists generate a significant amount of revenue through the same evaluation and management codes that primary care physicians use. By directing more money into those codes to boost pay for primary care physicians during the last 15 years, the CMS also has increased Medicare reimbursements to ophthalmologists. In this new proposed rule, CMS increased reimbursements to ophthalmologists by 1%, says William Rich III, MD, who practices at Northern Virginia Ophthalmology Associates in Falls Church, Virginia, and is medical director of health policy at the American Academy of Ophthalmology. The eye specialists had been slated for a 2% increase in total payments, but that was rolled back to 1% to help CMS fund the new discharge management code, Dr. Rich said.
That somewhat neutral budget outlook for ophthalmologists, however, turns bleak very quickly as Medicare moves away from a fee-for-service payment model to value-based care. There, too, Medicare is focused on primary care in the opportunities to bundle services to improve patient care and lower healthcare costs, but despite ophthalmologists' willingness to bundle care for such high-cost chronic eye ailments as macular degeneration, there is no opportunity to do so, Dr. Rich says. "Without any options, ophthalmologists are looking at potential cuts I, frankly, don't think are fair," he said in an interview with Medscape Medical News.
Funding Crisis in 2017
Other proposals wending their way through Congress or put forward by the Medicare Payment Advisory Commission would reduce Medicare payments to ophthalmologists by from 14% to 16%. Layered on top of that would be possible dramatic payment shifts from 2015 to 2017 because of nonparticipation in electronic health records.
"There really is a funding crisis around 2017," Dr. Rich said.
Rumors of more modest reductions in Medicare reimbursements are already having a chilling effect, said Charles Slonim, MD, president of the Florida Society of Ophthalmology, in an interview with Medscape Medical News.
When Dr. Slonim began his practice in 1982, Medicare reimbursed $1919 for cataract surgeries. Private insurers were more generous, reimbursing up to $2600. Although expensive lasers and ultrasound have replaced blades and knives in ophthalmologists' offices, Medicare now reimburses $791 for the procedure in the state of Florida, and private insurers pay from 80% to 90% of the Medicare rate.
At this point in their career, ophthalmologists such as Dr. Slonim would consider adding a partner, winding down their practice, and transferring skills to the next generation, but just as an uncertain economy chills other investment, unsteady Medicare reimbursements disrupt that calculus.
"As an older doc, you never know if you can take on a new partner," Dr. Slonim said.
The uncertainty filters down to students he teaches at the University of Florida and the University of South Florida.
"I see it in the residents and their fears," he said. "Because of the uncertainty of reimbursement, you just don't know what avenue to go down when it comes to becoming a specialist. Everything points to a constant reduction in income and not an increase in income to make up for the hard work."
On paper, such trims appear manageable. In reality, however, ophthalmologists have fixed overhead, with 65% of revenue consumed by personnel, software, and expensive hardware, including lasers, high-magnification slit lamps, and tools used to examine eyes from the outside in. A 14% to 16% reduction in Medicare reimbursements would translate to a 33% reduction in profits.
"It's huge. We do not have elastic overhead. We can't offshore things. The biggest asset we have to increase productivity is personnel," Dr. Rich said.
The significant funding challenges are projected to coincide with what's called the silver tsunami, a projected doubling of the number of Americans aged 65 years and older between 2010 and 2050. The extraordinary medical needs of aging Baby Boomers are projected to include failing vision.
Prevalence of cataracts is projected to increase by 50% from 2004 to 2020. Glaucoma affected 2.71 million Americans in 2011. That prevalence rate is expected to soar to 7.32 million in 2020. In addition, rates of macular degeneration may rise from 1.75 million cases in 2011 to 2.95 million cases in 2020, Dr. Rich said.
Ophthalmologists could meet the increased demands by working with teams of technicians and by using remote imaging to screen for pathology that needs treatment. The coping strategy, however, is thwarted by current CMS guidelines for office-based evaluation and management codes that require the physician to conduct all elements of an exam.
The CMS proposed rule will appear in the July 30 Federal Register. Comments will be accepted until September 4.

Comments

  1. Ophthalmologists is a eye physician who can help those people who suffering with cataract. Cataract is very serious disease in which people can loss their eye.

    What is Ophthalmology

    ReplyDelete

Post a Comment

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...